Abstract

T cells can mediate remarkable tumor regressions including complete cure in patients
with metastatic cancer. Genetic alterations in an individual’s cancer cells (the mutanome)
encode unique peptides (m-peptides) that can be targets for T cells. The recent advances
in next-generation sequencing and computation prediction allows, for the first time,
the rapid and affordable identification of m-peptides in individual patients. Despite
excitement about the extended spectrum of potential targets in personalized immunotherapy,
there is no experience or consensus on the path to their successful clinical application.
Major questions remain, such as whether clinical responses to cytokine therapy, T
cell transfer, and checkpoint blockade are primarily mediated by m-peptide-specific
reactivity, whether m-peptides can be effectively used as vaccines, and which m-peptides
are most potently recognized. These and other technological, immunological and translational
questions will be explored during a 1-day Workshop on Personalized Cancer Immunotherapy
by the Society for Immunotherapy of Cancer, directly before the Annual Meeting, on
November 7, 2013 at the National Harbor, MD near Washington, DC.